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Ethics approval was waived as this is a systematic review without patient identifiers. Patient consent was 
waived as this is a systematic review without patient identifiers. 
Abstract:  
Objectives: To assess the current state of knowledge for the utility of coronary calcium scoring (CCS) in connective 
tissue disorders (CTDs) as it relates to the presence/quantification of coronary atherosclerosis.
Methods: Following PRISMA guidelines, a literature search via PubMed, Embase, Scopus, Web of Science Core 
Collection, CINAHL, and Cochrane Database of Systematic Review retrieved 1019 studies (since database inception 
– May 7, 2018) from which 121 manuscripts were eligible for review. Inclusion criteria consisted of studies that 
investigated CCS in adults with respective CTDs. Studies were excluded if a complete manuscript was not written in 
English, or was a case report.
Results: 31 studies were included (27 with healthy age/gender matched control group for comparison and 4 
without). CTDs analyzed in articles with control group: 11 rheumatoid arthritis (RA), 14 systemic lupus 
erythematosus (SLE), 4 systemic sclerosis (SSc), 1 idiopathic inflammatory myopathies (IIM), 1 Takayasu arteritis, 
and 1 psoriasis. 9 out of 11 RA studies, 12 out of 14 SLE studies, and 2 out of 4 SSc studies showed statistically 
significant increased CCS when compared to control group. CTDs analyzed in studies without control group: 2 
Kawasaki disease, 1 juvenile idiopathic arthritis (JIA), and 1 antiphospholipid syndrome (APS) article which 
demonstrated increased coronary arterial calcium (CAC) burden, however, without statistically significant data. 
Conclusions: CTDs, especially SLE and RA, are associated with higher CCS compared to control group, indicating 
increased risk of coronary atherosclerosis. . Our search did not elicit sufficient publications or statistically 
significant results in many other connective tissue disorders.
Introduction
The association between atherosclerosis and inflammation has been well established (1). Atherosclerosis has been 
attributed to oxidative injury to the endothelial walls from inflammatory cells (2,3). Most connective tissue 
disorders (CTDs) are known chronic inflammatory disorders, of which some have been associated with 
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and rheumatoid arthritis (RA). One study demonstrated that the risk of cardiovascular disease in those with SLE 
was reported to be more than two times compared to their control group (4). Another study that investigated the 
risk of CVD in a multitude of inflammatory disorders found the highest risk in those with RA and other connective 
tissue disorders (5). The pathophysiologic mechanisms of why this occurs in diseases such as RA and SLE is still not 
fully understood, though inflammation seems to play a central role. Given the established association of 
atherosclerosis with inflammation, all connective tissue disorders should be investigated for their possible 
contributions for CVD.  
Traditional cardiovascular risk factors such as age, race, systolic blood pressure, cholesterol, diabetes, smoking, 
and others have been previously validated for their increased risk of cardiovascular disease, and have been used to 
predict the risk of future cardiovascular events (6). A growing number of studies suggest that inflammatory and 
autoimmune disorders have both a higher burden of atherosclerosis and a higher number of cardiovascular hard 
events (4, 5). Furthermore, there is a disproportionate rate of CVD seen in the younger population with CTDs who 
lack traditional cardiovascular risk factors which accrue with age (7). This could be explained by the ebb and flow 
of systemic inflammation which has been well described as an underlying mechanism of atherosclerotic plaque (1). 
The traditional  CVD risk stratification model might underestimate the true cardiovascular risks in CTDs, and new 
risk calculation models are needed.
Currently, there is no cardiac risk stratification model that includes pro-inflammatory CTDs as a risk factor for CVD. 
Coronary event risk calculators such as the American College of Cardiology/American Heart Association 
Atherosclerotic Cardiovascular Disease (ASCVD) risk calculator (6) do not include CTDs as a contributor to 
cardiovascular events. 
The impact of CTDs on one’s cardiovascular health is an important relationship to understand to be able to aid in 
its prevention. Surrogate markers for CVD such as coronary calcium score (CCS) have been shown to be an 
effective tool to predict increased risk of coronary heart disease events (8), such as myocardial infarction. The 
utility of CCS in identifying the cardiovascular risk in patients with CTDs has not been studied over the spectrum of 
CTDs (such as vasculitis, myositis, and mixed connective tissue disorders).
The purpose of this systematic review is to evaluate the coronary atherosclerotic disease risk of all connective 
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Methods
Protocol and registration
This descriptive systematic review was registered with PROSPERO (registration number CRD42019128607) and was 
performed following the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) (9). 
Search strategy
A structured search of published studies relating to coronary artery calcium scoring and connective tissue diseases 
was conducted in Medline via PubMed, Embase, Scopus, Web of Science Core Collection, CINAHL, and Cochrane 
Database of Systematic Review from database inception through May 7, 2018.
Search strategies were customized for each database and included appropriate controlled vocabulary terms and 
keywords related to coronary artery calcification and connective tissue disorders. Full details of the strategies for 
each database are available (Appendix 1). The reference lists of all included studies were hand searched to identify 
any additional relevant publications.
The Medical Subject Headings (MeSH) used to identify coronary artery calcification were the terms that were used 
to illustrate the connective tissue disorders and CT scan findings in the search concept (Table 1).
Eligibility criteria
Inclusion criteria consisted of studies that illustrated the CCS/CAC of the respective CTD in adults. Studies were 
excluded if they were a case report, not written in English, or were an abstract article without a full manuscript to 
evaluate. Each manuscript was evaluated to look for coronary arterial calcium detected from chest computed 
tomography scan in each respective connective tissue disorder (Figure 1).
Study selection, data extraction, and data items
Two reviewers evaluated the data and studies independently. 1907 abstracts were initially obtained from our 
search, which was reduced to 1019 after duplicates were removed. The 1,019 abstracts were analyzed for 
relevancy which resulted in 898 abstracts being excluded due to title and/or abstract that did not evaluate 
CCS/CAC of CTDs. 121 full manuscripts remained which were analyzed for mean, median, and/or 
prevalence/incidence of CCS/CAC in each respective CTD as either a primary outcome of the study, or as a 
secondary outcome. CCS/CAC was measured by CT scan of the chest without intravascular contrast and 
interpreted by a reviewer for CCS or CAC incidence/prevalence. All CT image modalities, including multidetector 
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the CCS was described by Agatston et al (10) and are reported in this review as Agatston units. Studies were also 
investigated for variables such as age, gender, ethnicity, and cardiovascular risk factors such as hypertension, 
diabetes, smoking, and hyperlipidemia. 
This search strategy resulted in 33 studies that were eligible for full manuscript review (Figure 1). 27 studies 
compared the CCS/CAC of the respective CTD to a control group, and 6 studies did not have a control group for 
comparison. Of these 6 studies, 2 were excluded (1 RA, 1 SLE) due to the sufficient number of higher quality RA 
and SLE studies which had a control group for comparison. The remaining 4 studies (2 Kawasaki disease, 1 juvenile 
idiopathic arthritis [JIA], and 1 antiphospholipid syndrome [APS]) were included in this review despite the absence 
of a control group for comparison due to the lack of better-quality studies that investigated this association. This 
resulted in a total of 31 articles that were evaluated in this systematic review. Of these, the quantity and type of 
CTDs analyzed with a control group for comparison were: 11 rheumatoid arthritis (RA), 14 systemic lupus 
erythematosus (SLE), 4 systemic sclerosis (SSc), 1 idiopathic inflammatory myopathies (IIM), 1 Takayasu arteritis, 
and 1 psoriasis. The quantity and type of CTDs analyzed without a control group for comparison were: 2 Kawasaki, 
1 JIA, and 1 APS.
Risk of bias in individual studies
The quality of articles included in this review were assessed using the Newcastle-Ottawa Scale (NOS) (11) 
assessment scale for cohort studies and the Agency for Healthcare Research and Quality (AHRQ) (12) criteria for 
cross-sectional studies. The Newcastle–Ottawa Scale assigns a maximum of 9 points to each study. The assessment 
scale analyzes three broad perspectives of each study: the selection of the study groups; the comparability of the 
groups; and the ascertainment of either the exposure or outcome of interest for case-control or cohort studies 
(11). When a study receives more than the median number of stars, it is considered to be of good quality (or low 
risk of bias); otherwise, it was deemed to be of low quality (or high risk of bias). All NOS assessments for cohort 
studies in this review had a score > 4 indicating good quality (Appendix 2). The individual assessments using AHRQ 
did not have a score value but did assess important study qualities through a series of investigational questions to 
assess for possible bias. The AHRQ assessment of the included cross-sectional studies subjectively demonstrated 
that they are also of good or fair quality (Appendix 3). 
Results:
CCS/CAC of CTDs compared to healthy matched control group (Table 2)
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11 rheumatoid arthritis, 14 systemic lupus erythematosus, 4 systemic sclerosis, 1 idiopathic inflammatory 
myopathy, 1 Takayasu arteritis, and 1 psoriasis article were analyzed. Not all studies investigated CCS in the 
respective CTD as a primary outcome yet were able to be included as they met inclusion/exclusion criteria. Some 
studies investigated the CCS/CAC of multiple CTDs compared to a control group. MDCT or EBT was used in these 
studies to detect CAC/CCS. Some articles (16, 18, 30) used participants from the Multi-Ethnic Study of 
Atherosclerosis (MESA) (40) study, which evaluated CAC in different ages, sex, ethnicities, and cardiovascular risk 
factors to match for their control group. Table 2 outlines details of each study, including the type of CTD, CCS/CAC 
findings, statistical significance, and sample size. Descriptive characteristics of each article are outlined in Appendix 
4. 
Rheumatoid Arthritis (RA)
9 out of 11 (82%) RA articles showed a statistically significant increase in CAC prevalence and/or CCS in RA patients 
compared to control group. Among the 9 articles, 3 of them (14, 15, 17) analyzed the CCS and CAC prevalence in 
early RA (<5 and <6 years disease duration) and late RA (>10-year duration). All of these studies found that the CAC 
prevalence and CCS were higher in the late RA group. One article (20) only analyzed female patients and control 
group. Two articles (16, 19) did not demonstrate increased CAC in RA, however, neither of these studies 
demonstrated statistical significance. One article (16) illustrated that both prevalence and progression of CAC were 
similar between the RA and control group, and the other (19) demonstrated that the median CAC was not 
increased in RA patients when compared to control group (in a small sample size of 37 patients).
Systemic Lupus Erythematosus (SLE)
12 out of 14 (86%) studies demonstrated with statistical significance that CCS, CAC incidence/prevalence, and/or 
CAC burden was increased in SLE when compared to control group. Three articles (28, 29, 30) only analyzed female 
patients and controls. One study (31) only analyzed male patients and controls. Two out of the fourteen studies did 
not comment on disease duration at time of CAC/CCS. The median or mean disease duration of the other twelve 
studies were at least >5 years duration. Of the 2 studies that did not demonstrate statistical significance, one study 
(29) showed that the SLE group had higher prevalence of CAC and higher rates of CAC progression when compared 
to control group. The other study (19) showed that the median CAC was not increased in SLE patients, but had a 
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2 out of 4 studies (50%) showed statistically significant increased CCS or CAC incidence/prevalence compared to 
control group, though one study (35) had a very small population size (17 patients for each group). The other two 
studies (19, 37) did not demonstrate statistical significance and illustrated that CAC/CCS was not increased in SSc 
when compared to control group. The mean or median disease duration in all studies was at least 6 years. 
Idiopathic Inflammatory Myopathy (IIM) also known as (Dermatomyositis [DM]/Polymyositis [PM])
One article (38) was reviewed which did show slight increase in the median CCS for IIM when compared to control 
group (not statistically significant; p=0.27). The mean disease duration was 9 years. The IIM group had more 
patients with CCS score ≥ 400 (20%) compared to control group (4%) (p=0.04). However, multivariate analysis 
demonstrated that the confounding factors associated with this were age and smoking, and there was no 
significant association found between the number of patients with higher CCS and IIM. 
Takayasu Arteritis
One article (33) was reviewed which illustrated increased CAC incidence in Takayasu arteritis when compared to 
control group, however, this data was not statistically significant. The mean disease duration was 9.5 years. This 
same study did show that the incidence of CAC was greater in SLE than in Takayasu arteritis (with statistical 
significance).
Psoriasis
One article (39) was reviewed which showed that those with psoriasis had slightly higher CCS than control group, 
however, this was not statistically significant. The mean disease duration was 16 years. The psoriasis and control 
group populations had similar prevalence of CAC.
CCS/CAC of CTDs without a control group for comparison (Table 3)
Connective Tissue Diseases Summary
The following articles were included in this study due to the lack of better-quality studies to evaluate CAC/CCS in 
these respective connective tissue disorders compared to a control group. These consisted of one antiphospholipid 
syndrome (APS) article (43) which analyzed serologically positive APS antibodies from a previous study (45) of 
patients that had CCS/CAC calculated, two Kawasaki articles (41, 42) which did not have a control group for 
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details of each study, including the type of CTD, CCS/CAC findings, statistical significance, and sample size. MDCT or 
EBT was used in these studies to detect CAC/CCS. The results demonstrate a higher CAC burden in people with 
these diseases than would be expected in their respective age groups, however, there is no control group for 
comparison, and data was not statistically significant. Descriptive characteristics of each article are outlined in 
Appendix 4.
Kawasaki Arteritis
Two articles (41, 42) were reviewed which demonstrated that CAC was increased in most patients with Kawasaki 
who developed a coronary aneurysm, though this data was not statistically significant. The median disease 
duration was at least 14.8 and 19.7 years. The median ages at the time of CT scan were 20 and 19.7 years in each 
study, respectively. There was no control group for comparison in either study. Both studies demonstrated that all 
of the participants without coronary dilation or aneurysm had no coronary arterial calcium detected.
Antiphospholipid Syndrome (APS)
One article (43) was analyzed from a pool of patients of the CARDIA study (Coronary Artery Risk Development in 
Young Adults) (45) which consisted of young adults aged 18-30 years old enrolled in the study in 1985. CAC was 
measured at 15 and 20 years. This study demonstrated that CAC was more prevalent in these patients with serum 
positivity for APS than would be expected for their age group. Antiphospholipid antibodies (IgG and IgA anti-β2-GPI 
antibodies) were associated with CAC > 0 at year 15 after adjustment for traditional cardiovascular factors, gender, 
and race. Anti-β2-GPI antibodies (more so anti-β2-GPI IgG) were associated with CAC > 0 at year 20, but the 
relationship was not as strong as that for CAC at year 15.
Juvenile Idiopathic Arthritis (JIA)
One article (44) discovered that 26% of patients were found to have CAC (not statistically significant), 
demonstrating an increased CAC burden than would be expected at this young age. The mean disease duration 
was 29.2 years, with a median age group of 38 years at the time of CT scan with CAC calculation. 
Discussion
The goal of this study was to evaluate the cardiovascular risk of connective tissue diseases as measured by 
coronary arterial calcium prevalence/incidence or coronary calcium score. Overall, the articles that compared their 
respective CTD to a control group effectively matched to age and gender, and had mostly similar cardiovascular 
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inclusion/exclusion criteria that evaluated CAC/CCS in connective tissue disorders besides SLE and RA. Therefore, 
this systematic review was unable to definitively assess the cardiovascular risk through means of CCS/CAC in the 
other connective tissue disorders, though the suspicion for cardiovascular disease is still high based on all of the 
studies evaluated. Nevertheless, this systematic review did confirm that there is a strong association of coronary 
artery calcification, and thus, coronary atherosclerosis in RA and SLE. All of the studies with statistical significance 
included in this systematic review that compared the RA and SLE patient population to a control group 
demonstrated increased CAC/CCS in the RA and SLE groups. Given these findings, CCS has shown to be an effective 
modality in the evaluation of coronary atherosclerosis in these two CTDs. It is important for future studies to 
address if the strict control of other risk factors of CAD such as hypertension, smoking, and hyperlipidemia, in 
addition to the control of disease activity itself, can assist in preventing future cardiovascular events in this patient 
population.
Systemic sclerosis had conflicting data on its cardiovascular risk, with half of the studies demonstrating increased 
CAC/CCS compared to control group. However, the two out of four studies with data of statistical significance did 
demonstrate increased CAC burden in the SSc group. In addition, one systematic review which investigated the 
incidence of CAD from autopsy findings, CAC, and coronary angiographic findings demonstrated that SSc is 
associated with increased incidence of CAD (46). These findings are more supportive of an increased cardiovascular 
burden from SSc, though additional studies with larger patient population sizes are needed to confirm this.  
One IIM study did show that patients with IIM had a higher number of individuals with CCS ≥400 than the healthy 
control group, however that was found to be attributed to confounding risk factors of tobacco smoking and patient 
age, and not IIM. More studies are needed to investigate this correlation. The Takayasu arteritis and psoriasis 
studies also demonstrated increased CAC (though not statistically significant), however, more studies are needed 
with a larger patient population size for reliable assessment.
Overall, the analysis of articles without a control group for comparison demonstrated higher CAC/CCS in the 
Kawasaki, APS, and JIA population than would be expected for their younger patient population (not statistically 
significant), but additional studies are needed for direct comparison to a control group, as well as larger sample 
sizes. Kawasaki disease is unique in that there is a direct coronary artery injury in the pediatric population 
complicated by post traumatic effects such as coronary aneurysm. These studies were consistent in finding that 
those with coronary aneurysms did have increased CAC, though the data was not statistically significant. The JIA 
study also demonstrated increased CAC prevalence than would be expected in its young patient population. The 
APS study showed a CAC burden greater than zero in those with serum positivity for antiphospholipid antibodies 
which is not expected to be found in a young population of age 18-30 years old, however, a control group would 
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This systematic review has several limitations. First, this is a descriptive review and lacks statistical analysis to 
summarize the results of these studies and assist in eliminating some bias. The authors believe that publication 
bias could be present but cannot be assessed in this review due to the different expected magnitude of effect and 
different publication bias across these connective tissue disorders.
Another limitation of this study is the few number of articles that studied CCS in CTDs besides SLE and RA, which 
prevents proving or disproving the hypothesis that CCS/CAC is higher in all CTDs when compared to healthy control 
groups. Third, this review included many cross-sectional observation studies which could not evaluate the 
temporal relationship of each respective CTD and coronary arterial calcification.  
Conclusion
From the evidence of articles evaluated, this systematic review demonstrates that some CTDs (RA and SLE) have 
higher CCS and/or CAC incidence or prevalence compared to normal controls, and thus, may be an independent 
risk factor of coronary atherosclerosis, while the SSc data is still ambiguous. For SLE and RA, we suggest this risk 
from studies that demonstrated this association with statistical significance, though the quality of the articles 
evaluated (cross sectional and cohort studies) must be considered. Based on the current published data regarding 
other CTDs, increased coronary atherosclerosis also seems likely, however better-quality studies are needed to 
prove this association. This review also identified that aside from Takayasu arteritis and Kawasaki disease, there is 
currently no published data in the spectrum of vasculitides, which have been associated with high inflammatory 
burden. It is unclear if MDCT or EBT-measured CCS is a reliable and generalizable tool to assess subclinical 
atherosclerosis across the spectrum of CTDs, however we ascertain that it can be useful for cardiovascular risk 
assessment in patients with SLE and RA, with consideration of its disadvantages including radiation exposure and 
cost.
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c. Enteropathic Arthropathy OR Spondylitis Associated with Inflammatory Bowel Disease
d. Psoriatic Arthritis
e. Undifferentiated Spondyloarthropathy
3. Connective Tissue Diseases
a. Systemic Sclerosis
b. Primary Sjogren’s Syndrome
c. Systemic Lupus Erythematosus
d. Antiphospholipid Syndrome
e. Relapsing Polychondritis
f. Idiopathic inflammatory myopathies: Polymyositis, Dermatomyositis, Anti-synthetase 
Syndrome, Inclusion-body Myositis, Necrotizing Autoimmune Myopathy
g. Mixed Connective Tissue Disorder
h. Undifferentiated Connective Tissue Disease
4. Vasculitis:
a. Large vessel vasculitis:
i. Takayasu Arteritis
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b. Medium vessel vasculitis:
i. Polyarteritis Nodosa
ii. Kawasaki Disease
c. Small vessel vasculitis
i. Microscopic Polyangiitis
ii. Granulomatosis with Polyangiitis 
iii. Eosinophilic Granulomatosis with Polyangiitis
d. Variable vessel vasculitis
i. Behcet’s Disease
ii. Cogan’s Syndrome
e. Immune complex small vessel vasculitis
i. Anti-glomerular Basement Membrane (anti-GBM) Disease
ii. Cryoglobulinemic Vasculitis
iii. IgA Vasculitis (Henoch-Schonlein)
iv. Hypocomplementemic Urticarial Vasculitis (anti-C1q vasculitis)
Table 1. Search terms for connective tissue disorders
Author, Year, & 
Reference CTD / Sample size








RA Mean CCS: 126 ± 115.23 
Control Mean CCS: 4.7 ± 4.03 p < 0.001
Asanuma (2007) 
(14)
Early RA - 90
Established RA - 67 
Control - 87 
Early RA (< 6 years) Median CCS: 0 (0-47)
Established RA (> 10 years) Median CCS: 63 (0-368)
Control Median CCS: 0 (0-18) p < 0.001
Avalos (2007) 
(15)
Early RA - 57 
Late RA - 60 
Control - 65 
Early RA (< 6 years) – Median CCS 0 (0–33.8) 
Late RA (> 10 years) – Median CCS 65.5 (0–400.5)
Controls – Median CCS  0 (0–16.4) p < 0.001
Chung (2013) 
(16)
RA - 155 
Control – 835*
Median CCS RA - 3.1 (0-135.1)
Median CCS control - 6.4 (0-119.6) NS
Chung (2005) 
(17)
Early RA - 70
Established RA - 71 
Control - 86 
Early RA (< 5 years) - median CCS 0 (0-42.6), CAC in 42.9% 
Established RA (> 10 years) - median CCS 40.2 (0-358), CAC in 60.6% 
Control - median CCS 0 (0-19.2), CAC in 38.4% p = 0.001 
Giles (2009) 
(18) 
RA - 195 
Control - 1,073*
RA mean CCS: 175 ± 31
Control mean CCS: 122 ± 13 p = 0.002
Kakuta (2016) 
(19) 
RA - 37 
SSc - 24 
SLE - 33 
Control - 74 
Median CCS RA – 0 (0-136)
Median CCS SSc – 0 (0-111)
Median CCS SLE – 0 (0-138)
Median CCS Control – 30 (0-225) NS
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Table 2. Descriptive summary of CCS/CAC of CTDs with control group for comparison; CAC = coronary artery calcium; CCS = coronary 
calcium score; RA = rheumatoid arthritis; SLE = systemic lupus erythematosus; SSc = systemic sclerosis; IIM = idiopathic inflammatory 
myopathy; NS = not significant; * = sample patients from (40) Multi-Ethnic Study of Atherosclerosis [MESA] Study
RA – 105
Control – 105
SLE - 47.6%, RA - 47.6%, Control - 35.2%
Paccou (2014) 
(21)
RA - 75 
Control - 75 
RA CAC prevalence - 65.3%
Control CAC prevalence - 49.3% p = 0.04
Wang (2009) 
(22)
RA - 85 
Control - 85 
RA Mean CCS - 62.8 ± 197.0
Control Mean CCS - 11.3 ± 38.5
p = 0.002
Yiu (2012) (23)
RA - 85 
SLE - 69 
Control - 106 
RA and SLE Mean CCS - 42.2 ± 154.3





SLE Mean CCS: 68.9 ± 244.2
Control Mean CCS: 8.8 ± 41.8 p = 0.002
Chung (2006) 
(25)
SLE - 93 
Control – 65
SLE CAC incidence and Mean CCS - 19.4% and 39 ± 200
Control CAC incidence and Mean CCS - 6.2% and 4 ± 30 p = 0.02
Chung (2008) 
(26)
SLE - 113 
Control - 80 
SLE Mean CCS - 43.4 ± 189.8 
Control Mean CCS - 3.8 ± 27.9 p = 0.002
Heshmat (2015) 
(27)
SLE - 30 
Control - 30 
SLE Mean CCS: 42 ± 111.09
Control Mean CCS: 0, no CAC was detected p = 0.04
Kiani (2015) 
(28)
SLE - 80 
Control – 241*
Age 45-54 CAC prevalence: SLE - 58%. Control - 22/125 (36%)
Age 55-64 CAC prevalence: SLE - 57%. Control - 42/116 (36%)





Control - 124 






SLE Mean CCS - 59.2 ± 20.3
Control Mean CCS - 2.6 ± 1.85 p < 0.001
Romero-Diaz 
(2018) (31)
SLE - 95 
Control - 100 
SLE - CAC incidence 18%
Control - CAC incidence 7% p = 0.03
Romero-Diaz 
(2012) (32)
SLE - 139 
Control - 100 
SLE - CAC incidence 7.2%
Control - CAC incidence 1% p = 0.02
Seyahi (2013) 
(33)
Takayasu - 47 
SLE - 43 
Control - 70 
Takayasu CAC incidence: 11%
SLE CAC incidence: 21%
Control CAC incidence: 3%
Takayasu: NS
SLE: p = 0.010
Yiu (2009) (34)
SLE - 50 
Control - 50 
SLE CAC prevalence - 42%
Control CAC prevalence - 8% p < 0.01
Khurma (2008) 
(35)
SSc - 17 
Control - 17 
SSc Mean CCS - 126.6 ± 251.0
Control Mean CCS - 14.7 ± 52.2 p = 0.003
Mok (2011) (36)
SSc - 53 
Control - 106 
SSc - 56.5% had CCS > 101
Control - 29.4% had CCS > 101 p = 0.01
Seung-Geun 
(2013) (37)
SSc - 41 
Control – 123
SSc median CAC – 0 (0-133.5)





IIM: Median CCS 18 (0 - >400)
Control: Median CCS 5 (0 - >400) NS
Seremet (2014) 
(39)
Psoriasis - 40 
Control - 42 
Psoriasis Mean CCS - 9.9 ± 35.2
Control Mean CCS - 2.8 ± 12.0 NS
Author, Year, & 
Reference
CTD / Sample 
Size








No coronary dilation (44/70) - none had CAC
Transient dilation (12/70) - 1/11 patients had CAC
With coronary aneurysm (14/70) – all patients had CAC and the highest 
CAC burden
NS





No coronary dilation (100/160) - 0 CAC
Transient/persistent dilation (33/160) – 1 out of 33 patients had CAC
Aneurysm (9/33) – all had CAC and the highest CAC burden
NS





APS: CAC was prevalent in 9.5% of young adults (age 18-30) with APS 
antibodies.
NS
Aulie et al. (2014) (44)
JIA – 84 
No control 
group
22 of 84 JIA patients (26%) had a CCS above 0
16 patients had CCS 1-10
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Table 3. Descriptive summary of CCS/CAC of CTDs without control group for comparison; CAC = coronary artery calcium;  CCS = coronary 
calcium score; APS = antiphospholipid syndrome; JIA = juvenile idiopathic arthritis; NS = not significant; * = sample patients from (45) 













































Records identified using PubMed, 
Embase, Scopus, Web of Science, 
CINAHL, Cochrane CENTRAL  
(n = 1,907) 
 
Records after duplicates removed 
(n = 1,019) 
Records screened: 
Abstracts (n = 1,019) 
Abstracts excluded 
(n = 898)  
After title and/or abstract 
screening that did not evaluate 
CCS/CAC of CTD 
 
Full-text articles assessed for 
eligibility 
(n = 121) 
Full-text articles excluded 
(n = 88) due to: 
Case report 
Not written in English 
CCS/CAC not reported 
Incomplete manuscript 
 
Studies included in qualitative analysis 
with control group for comparison 
(n = 27) 
Figure 1. Flow Diagram - Search design 




Studies analyzed without control group for 
comparison 
(n=6) 
2 articles removed (1 lupus, 1 rheumatoid 
arthritis) due to their sufficient number of 
articles with control group comparison 
 
Studies included in qualitative analysis 
without a control group for comparison 
(n = 4) 
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